



International Symposium on Immunotherapy and Immunodeficiency



November 19th – 20th, 2009
Lecture Hall,
German Cancer Research
Center (DKFZ)

Im Neuenheimer Feld 280
69120 Heidelberg, Germany



HELMHOLTZ
ASSOCIATION

Alliance on Immunotherapy of Cancer



NCT

NATIONALES CENTRUM
FÜR TUMORERKRANKUNGEN
HEIDELBERG

getragen von:
Deutsches Krebsforschungszentrum
Universitätsklinikum Heidelberg
Thoraxklinik-Heidelberg
Deutsche Krebshilfe

Welcome


Dear Colleagues,

The immune system plays an important role during tumor development and progression. Cellular immune responses can be very powerful as seen in transplant rejection or graft versus host disease.

Therapeutic strategies utilizing tumor directed cellular immune responses are still experimental, whereas antibody based therapies are already standard of care in many tumor entities.

The Helmholtz Alliance on Immunotherapy of Cancer and the National Center for Tumor Diseases (NCT) Heidelberg have gathered many of the world wide leading experts on T lymphocyte physiology, immunodeficiency and lymphocyte based tumor therapy to reflect the current understanding of tumor immunology and discuss future therapeutic strategies.

We are happy to welcome you to our symposium on 19th – 20th November, 2009 in the beautiful city of Heidelberg to hear about the latest development and discuss critical issues of Immunotherapy and Immunodeficiency.



Dirk Jäger
Director Medical Oncology,
NCT Heidelberg



Christoph von Kalle
Director Translational Oncology,
NCT Heidelberg



Peter Krammer
Division of Immunogenetics,
DKFZ Heidelberg



Stefan Meuer
Institute for Immunology,
University Heidelberg

Directions

Location of the Lecture Hall of the German Cancer Research Center.

German Cancer Research Center, Lecture Hall
Im Neuenheimer Feld 280,
69120 Heidelberg, Germany



Thursday, November 19th, 2009

8:15 **Welcome**

Wiestler, Otmar D.

Immunodeficiencies and gene therapy I

Chair: *Williams, David; von Kalle, Christof*

- 8:30 Clinical presentation, classification and genetics of common variable immunodeficiency
Peter, Hans-Hartmut
- 9:00 Severe combined immunodeficiency: from molecular immunology to therapy
Cavazzana-Calvo, Marina
- 9:30 Gene therapy for combined immunodeficiencies: from preclinical to clinical studies
Aiuti, Alessandro
- 10:00 Update on gene therapies for SCID
Thrasher, Adrian
- 10:30 Gene therapy for HIV: lessons learned and future decisions
Symonds, Geoff
- 11:00 **Coffee**

Immunodeficiencies and gene therapy II

Chair: *Cavazzana-Calvo, Marina ; Peter, Hans-Hartmut*

- 11:30 Gene therapy of chronic granulomatous disease: lessons, chances and challenges
Grez, Manuel
- 12:00 The clonal repertoire of the gene-modified human immune system
von Kalle, Christof
- 12:20 Novel genetic defects of immunity – from molecular diagnosis to gene therapy
Klein, Christoph
- 12:50 Hematopoietic cell gene therapy for X-linked adrenoleukodystrophy
Cartier, Nathalie



Thursday, November 19th, 2009

13:20 Improving safety and efficacy of gene therapy by
lentiviral vectors
Naldini, Luigi

13:50 **Lunch**

Mechanisms and targets in immunotherapy I

Chair: *Greenberg, Philip D.; Krammer, Peter*

15:00 The utility of induced pluripotent stem cells
in treatment of genetic blood diseases
Williams, David

15:30 Molecular pathways in Notch-dependent acute
lymphoblastic T cell leukemia
von Boehmer, Harald

16:00 Regulatory T cells for immune tolerance and
tumor immunity
Sakaguchi, Shimon

16:30 Cancer immunoediting: mechanistic insights and
therapeutic implications
Schreiber, Robert

17:00 No escape
Blankenstein, Thomas

17:20 **Coffee**

Mechanisms and targets in immunotherapy II

Chair: *Allison, James; Jäger, Dirk*

17:50 Tumor stroma and immune response
Schreiber, Hans

18:20 Melanoma genetics – implications for
tumor immunogenicity and immunotherapy
Schadendorf, Dirk

18:40 Regulation of T cell responses against cancer
Beckhove, Phillip

19:00 End

Friday, November 20th, 2009

Pathways of therapeutic intervention

Chair: *Melief, Cornelis; Kirkwood, John*

- 8:15 Resistance and sensitivity towards induction of apoptosis
Krammer, Peter
- 8:35 The role of IL-15 in the life and death of lymphocytes: implications for cancer therapy and vaccine design
Waldmann, Thomas
- 9:05 Immunological side effects of MAP kinase inhibitors for the recognition of tumor cells by cytotoxic T cells and NK cells
Falk, Christine
- 9:25 Dendritic cell priming of high avidity allorestricted, peptide-specific T cells
Schendel, Dolores
- 9:45 Acute hepatitis C – presentation and management
Manns, Michael
- 10:05 **Coffee**

T cell therapy

Chair: *Huber, Christoph; Meuer, Stefan*

- 10:30 Adoptive transfer of natural Treg cells in stem cell transplantation
Edinger, Matthias
- 11:00 Allogeneic immunotherapy of hematologic malignancies
Storb, Rainer
- 11:30 New aspects of the GVL reaction
Kolb, Hans-Jochem
- 11:50 New approaches for adoptive T cell transfer as treatment for hematological malignancies upon bone marrow transplantation
O'Reilly, Richard
- 12:20 Development of effective T cell adoptive cancer immunotherapies
Robbins, Paul



Friday, November 20th, 2009

12:50 T cell recognition of tumors: creating responses that can be effective in vivo
Greenberg, Phillip

13:30 **Lunch**

Novel strategies in immunotherapy

Chair: *Schendel, Dolores; von Boehmer, Harald*

14:30 Systemic therapy of melanoma
Kirkwood, John

15:00 Targeting cancer stem cells
Cebon, Jonathan

15:30 Overview of the cancer vaccine collaborative international clinical trials program
Gnjatic, Sacha

16:00 Peptide-based vaccines for the immunotherapy of melanoma
Romero, Pedro

16:30 Strategies for immunotherapy of established disease caused by high risk human papilloma viruses
Melief, Cornelis

17:00 **Coffee**

Clinical intervention

Chair: *Schreiber, Robert; Storb, Rainer*

17:30 Checkpoint blockade in immunotherapy
Allison, James

18:00 Targeting dendritic cells in vivo – a novel approach to cure cancer
Enk, Alexander

18:20 A novel paradigm for cancer
Galon, Jerome

18:50 Characterization of anti-tumor immune responses: implication for treatment decisions
Jäger, Dirk

19:10 End

Speakers and Chairpersons

Aiuti, Alessandro

MD, PhD, San Raffaele Telethon Institute for Gene Therapy, Milan; Italy

Allison, James

PhD, Institute for Immunology, Memorial Sloan-Kettering Cancer Center, New York; USA

Beckhove, Philipp

MD, Research Group Translational Immunology, German Cancer Research Center, Heidelberg; Germany

Blankenstein, Thomas

PhD, Department of Molecular Immunology and Gene Therapy, Max-Delbrück-Centrum, Berlin; Germany

Cartier, Nathalie

MD, PhD, INSERM, Hôpital Saint Vincent de Paul, Paris; France

Cavazzana-Calvo, Marina

MD, PhD, Department of Biotherapy at Necker Children's Hospital, Paris; France

Cebon, Jonathan

MD, Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences – Cancer Vaccine Laboratory; Australia

Edinger, Matthias

MD, Department of Haematology and Oncology, University Hospital Regensburg; Germany

Enk, Alexander

MD, Department of Dermatology, University Hospital Heidelberg; Germany

Falk, Christine

PhD, Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and Institute for Immunology, University Heidelberg; Germany



Speakers and Chairpersons

Galon, Jerome

PhD, Cordeliers Research Centre, INSERM Paris; France

Gnjatic, Sacha

PhD, Ludwig Institute for Cancer Research at Memorial Sloan-Kettering Cancer Center, New York; USA

Greenberg, Philip D.

MD, PhD, Fred Hutchinson Cancer Research Center, Seattle; USA

Grez, Manuel

PhD, Georg-Speyer-Haus Frankfurt, Institute for Biomedical Research; Germany

Huber, Christoph

MD, Department of Internal Medicine III, University Medical Center of the Johannes Gutenberg University Mainz; Germany

Jäger, Dirk

MD, Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg; Germany

Kirkwood, John

MD, Division of Hematology/Oncology, University of Pittsburgh, Medical Center; USA

Klein, Christoph

MD, PhD, Department of Pediatric Hematology, Oncology, Hannover Medical School; Germany

Kolb, Hans-Jochem

MD, Medizinische Klinik und Poliklinik III, Klinikum der Universität München-Großhadern; Germany

Krammer, Peter

MD, Division Immunogenetics, German Cancer Research Center, Heidelberg; Germany

Speakers and Chairpersons

Manns, Michael

MD, Department of Gastroenterology, Hepatology and Endocrinology, Centre for Internal Medicine, Hannover Medical School; Germany

Melief, Cornelis

MD, PhD, Department of Immunohematology and Blood Transfusion, Leiden University; Netherlands

Meuer, Stefan

MD, Institute for Immunology, University Heidelberg; Germany

Naldini, Luigi

MD, PhD, San Raffaele Telethon Institute for Gene Therapy, Milan; Italy

O'Reilly, Richard

MD, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York; USA

Peter, Hartmut

MD, Department of Rheumatology and Clinical Immunology, University Hospital Freiburg; Germany

Robbins, Paul

PhD, Tumor Immunology Section, National Cancer Institute, Bethesda; USA

Romero, Pedro

MD, Ludwig Institute for Cancer Research, Lausanne Branch; Switzerland

Sakaguchi, Shimon

MD, PhD, Institute for Frontier Medical Sciences, Kyoto University; Japan

Schadendorf, Dirk

MD, Department of Dermatology, Venerology and Allergology, University of Essen, Medical Center; Germany



Speakers and Chairpersons

Schendel, Dolores

*PhD, Institute of Molecular Immunology,
Helmholtz-Zentrum München; Germany*

Schreiber, Hans

MD, PhD, Department of Pathology, University of Chicago; USA

Schreiber, Robert

*PhD, Department of Pathology & Immunology,
Washington University – School of Medicine; USA*

Storb, Rainer

*MD, Transplantation Biology Program,
Fred Hutchinson Cancer Research Center, Seattle; USA*

Symonds, Geoff

PhD, Calimmune Inc., Sydney; Australia

Thrasher, Adrian

*MD, PhD, University College London, Institute of Child Health;
United Kingdom*

von Boehmer, Harald

*MD, PhD, Laboratory of Lymphocyte Biology,
Dana Farber Cancer Institute, Boston; USA*

von Kalle, Christof

*MD, PhD, Translational Oncology, National Center for
Tumor Diseases (NCT) Heidelberg; Germany*

Waldmann, Thomas

*MD, Cytokine Immunology and Immunotherapy Section,
National Cancer Center, Bethesda; USA*

Wiestler, Otmar D.

*MD, Chairman and Scientific Director;
German Cancer Research Center, Heidelberg; Germany*

Williams, David

MD, Div. Hematology/Oncology, Children`s Hospital Boston; USA

Information and Contact

Date:

November 19th – 20th, 2009

Location:

Lecture Hall

German Cancer Research Center (DKFZ)

Im Neuenheimer Feld 280

69120 Heidelberg, Germany

Information and Registration:

Dr. Astrid Beiglböck

Coordinator of the Medical Oncology at the National
Center for Tumor Diseases (NCT) Heidelberg

Im Neuenheimer Feld 350

69120 Heidelberg, Germany

Phone: +49 (0) 6221 56-6904

Fax: +49 (0) 6221 56-7225

E-mail: astrid.beiglboeck@nct-heidelberg.de

Online-Registration:

<http://immunotherapy.nct-meeting.de>

Regular fee 250 €

Reduced rate 125 € (PhD Students, Students)



Alliance on Immunotherapy of Cancer



NATIONALES CENTRUM
FÜR TUMORERKRANKUNGEN
HEIDELBERG

getragen von:
Deutsches Krebsforschungszentrum
Universitätsklinikum Heidelberg
Thoraxklinik-Heidelberg
Deutsche Krebshilfe